Cyclacel faces going concern warning; cash of $3.45M expected only into Q2 2025

Bio Green Med Solution, Inc.

Auditor expresses substantial doubt about Cyclacel's ability to continue as a going concern; cash of $3.45M at March 31, 2025, expected to fund only into Q2 2025.
Net loss of $81k for Q1 2025 vs $2.9M in Q1 2024, largely due to a $4.9M gain from deconsolidation of UK subsidiary Cyclacel Limited on Jan 24, 2025.
Operating loss of $5.0M; R&D expenses fell to $822k from $2.8M, while G&A rose to $4.2M from $1.6M, partly due to $1.7M stock-based compensation.
Issued Series D and E preferred stock and converted shares; common shares outstanding surged from 8.9M to 207.3M during Q1 2025.
Regained Nasdaq compliance with equity rule on Feb 25, 2025; subject to one-year mandatory panel monitor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.